These are hard times for early stage ideas to become commercial realities. Patients are not benefi ting from promising new treatments. Until recently industry was only interested in less risky later stage products. Today, there is a better win-win approach. Start-ups provide promising programs to pump up dwindling industry pipelines. In return start-ups obtain the necessary financial, regulatory and legal support as well as increased visibility through industry affiliations. This session focuses on the increasing industry trend to nurture early stage programs and will provide the details of the leading business models and scientific collaborations in the industry today. Current in-house incubators and extramural programs will be covered.

• Provide information on current industry models for supporting promising early stage products
• Discuss the pros and cons of business and scientific strategies in the US and internationally
• Discuss future improvements, trends and projected needs of to continue industry support of start-ups